2 studies found for:    AP26113
Show Display Options
Rank Status Study
1 Recruiting A Multicenter Study (ALTA) of AP26113
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Interventions: Drug: AP26113 (90 mg);   Drug: AP26113 (90 mg /180 mg)
2 Recruiting A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Conditions: Advanced Malignancies;   Carcinoma, Non-Small-Cell Lung;   Anaplastic Large Cell Lymphoma;   Diffuse Large Cell Lymphoma;   Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113

Indicates status has not been verified in more than two years